> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vertex Wins Priority Review Voucher
- URL: https://www.fdaweb.com/vertex-wins-priority-review-voucher/
- Published: 2020-09-15T12:00:00.000Z
- Updated: 2026-09-14T16:28:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147648

*Federal Register* notice: FDA has announced that it issued a priority review voucher to Vertex Pharmaceutical for Trikafta (elexacaftor/tezacaftor/ivacaftor), indicated for treating patients with cystic fibrosis aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-09-15/pdf/2020-20320.pdf?ref=fdaweb.com).